Showing 1-10 of about 72 articles.
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines,...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines,...
Evelo Biosciences, Inc.
–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured physician-reported outcomes – –Improvements in patient-reported outcomes in DLQI and POEM,...
Evelo Biosciences, Inc.
-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates...
Evelo Biosciences, Inc.
–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503––Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product...
Evelo Biosciences, Inc.
–Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores––EDP1815 first-ever candidate targeting SINTAX™ to show clinical activity in...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act...
Showing 1-10 of about 72 articles.
